Articles & Video
Can payment models for gene therapies evolve fast enough to keep up?
Gene therapy is revolutionizing healthcare, but can we revolutionize payment models in time to keep up?
HCEI and PIE: Is it time for pharma to be proactive in the argument over cost effectiveness?
How can drug manufacturers embracing the FDA's new HCEI and PIE guidance to engage payer customers early? Jeremy Schafer, PharmD, MBA, SVP, Precision for Value explores.
Social Determinants of Health: Methods of Success - WHITEPAPER
Medicaid Managed Care: Discover methods of success for Social Determinants of Health in this whitepaper.
Point-of-prescribing drug cost-share transparency: How does it change the dynamic?
How is HR 2115 going to impact healthcare transparency, providers, patients and brand manufacturers?
Moment of truth: Term sheet negotiations reveal more than you might expect
The thought of negotiating the terms and conditions for a partnership with a pharma company or other third party is often full of ambiguity or anxiety for biotech innovators and executives. But when approached with the right mindset, the process can provide critical insights while smoothing the way for contract negotiations down the road.